Contents
01 February 2017
Vol 9, Issue 375
Vol 9, Issue 375
Focus
- Blunting CHIKV infection by keeping T cells in check
Modulating the host immune response ameliorates arthritic disease in mice infected with chikungunya virus (Miner et al. and Teo et al.).
Research Articles
- Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis
Combination therapy with CTLA4-Ig and an antiviral human monoclonal antibody controls chikungunya virus arthritis in mice.
- Fingolimod treatment abrogates chikungunya virus–induced arthralgia
Abrogation of pathogenic CD4+ T cells to the joints with fingolimod (FTY720) treatment prevents chikungunya virus–induced joint pathology.
- 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
The oncometabolite 2-hydroxyglutarate renders IDH1/2 mutant cancer cells deficient in homologous recombination and confers vulnerability to synthetic lethal targeting with PARP inhibitors.
- Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertension
Blockade of an inflammatory, thrombin-activated feedback loop on platelets controls high blood pressure.
- Tumor-homing cytotoxic human induced neural stem cells for cancer therapy
Human skin cells directly converted to induced neural stem cells seek out cancer foci and deliver therapeutic agents that inhibit glioblastoma progression.
Editors' Choice
- Real life zombie apocalypse in New York City
Synthetic cannabinoid use elicits “zombie-like” symptoms in New York.
- Monkey business: Repurposing a protein from the simian immunodeficiency virus to enhance cytotoxic chemotherapy
Cytarabine activity in acute myeloid leukemia blasts can be augmented by degrading the expression of a critical hydrolase.
- The tip of the thrombos-is-berg
A high risk of venous thromboembolic events is just one of the challenges faced by people with malignant brain tumors.
- Resveratrol for Alzheimer’s disease?
Resveratrol modulates β-amyloid levels and inflammatory markers in patients with Alzheimer’s disease.
About The Cover
ONLINE COVER Brainy Skin Cells. Neural stem cells can home to brain tumors and deliver therapeutics. Unfortunately, isolating and customizing neural stem cells for each patient is not feasible, and treatment with donor stem cells requires immunosuppression. Bagó et al. came up with a more practical approach to this problem, showing that a patient's skin cells can be converted to neural stem cells and engineered to attack brain tumors. The image depicts engineered DNA molecules going into the cells, the conversion from skin to neural stem cells, and their subsequent delivery to the brain. [CREDIT: ELLA MARUSHCHENKO]
